

# Uri Abadi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8149840/publications.pdf>

Version: 2024-02-01

15  
papers

386  
citations

1307594

7  
h-index

1125743

13  
g-index

15  
all docs

15  
docs citations

15  
times ranked

341  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nuclear $\alpha$ <sup>v</sup> $\beta$ <sup>3</sup> integrin expression, post translational modifications and regulation in hematological malignancies. <i>Hematological Oncology</i> , 2022, 40, 73-82.	1.7	3
2	Polatuzumab-based regimen or CAR T cell for patients with refractory/relapsed DLBCL—a matched cohort analysis. <i>Annals of Hematology</i> , 2022, 101, 755.	1.8	1
3	The utility of the novel optimized HLH inflammatory (OHI) index for predicting the risk for mortality and causes of death in lymphoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7570-7570.	1.6	0
4	Outcome of relapsed/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 118-124.	1.3	23
5	Real-World Efficacy of Venetoclax-Based Regimens in Patients with Chronic Lymphocytic Leukemia in Israel: A Multicenter Prospective Study. <i>Blood</i> , 2021, 138, 3727-3727.	1.4	2
6	Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 43-45.	1.4	41
7	Prevalence and clinical significance of hypercalcemia at diagnosis in diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 2922-2926.	1.3	7
8	Hemophagocytic lymphohistiocytosis as a harbinger of aggressive lymphoma: a case series. <i>International Journal of Hematology</i> , 2019, 109, 553-562.	1.6	14
9	The induction of myeloma cell death and DNA damage by tetrac, a thyroid hormone derivative. <i>Endocrine-Related Cancer</i> , 2018, 25, 21-34.	3.1	10
10	Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e401-e419.	0.4	61
11	Can We Improve the Predictive Value of Interim PET/CT Using a New Prognostic Model for Advanced Hodgkin Lymphoma?. <i>Blood</i> , 2016, 128, 3001-3001.	1.4	0
12	Analysis of Final Data from the Multinational, Non-Interventional, Observational Emmos Study (NCT01241396) in Patients (Pts) with Multiple Myeloma (MM) in Real-World Clinical Practice. <i>Blood</i> , 2015, 126, 3034-3034.	1.4	1
13	Tailored Therapy in Hodgkin Lymphoma, Based on Predefined Risk Factors and Early Interim PET/CT: Israeli H2 Study. <i>Blood</i> , 2014, 124, 4409-4409.	1.4	3
14	Leukemia and Lymphoma in Pregnancy. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 277-291.	2.2	215
15	Myositis in Behcet's disease after tonsillectomy. <i>Israel Medical Association Journal</i> , 2006, 8, 294-5.	0.1	5